AG1 — campaign lander (May 2026)
The page AG1's own ads point at. Origin blocks this host, so this is the archive.
12,646px tall
Every page behind the research, with a live link and the full-page capture the analysis was run against. Thumbnails are clipped — click a thumbnail for the whole page, or the link for the real thing. AG1 blocks this host at origin, so those three are Wayback snapshots.
The page AG1's own ads point at. Origin blocks this host, so this is the archive.
12,646px tall
Shorter, tighter version. 9,744px. The better model of the two.
9,744px tall
THE DIRECT COMPETITOR. Same molecule, same 15 mg dose. This page argues a standalone methylfolate — ours — fails without B12.
8,135px tall
The Harvard headline and the 10-box symptom checklist.
13,238px tall
Their version of our folic-acid argument, run much harder.
8,153px tall
Another angle, another page.
13,195px tall
Their live cold traffic goes here, not to the presells.
9,670px tall
Best-scoring competitor in the blind panel (7.12). The Monthly Stress Receipt is here.
12,585px tall
First-person exposé. Argues AGAINST methylfolate.
15,177px tall
240 days of continuous paid spend — the longest-running in the set.
17,222px tall
Same brand, listicle format.
18,218px tall
Lowest scorer (4.06). Its offer module renders a Product not found error.
6,864px tall
Benefit-forward, no pain language at all.
11,383px tall
914 days running. The longest-surviving page found anywhere in this research.
13,128px tall
Scored 8.41, rank 1 of 5, in the first blind panel.
19,672px tall
Rebuilt to the category's register.
17,630px tall
Current. Full-bleed bands, dark figures, two reasons cut.
21,255px tall